These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Tohen M; Kryzhanovskaya L; Carlson G; Delbello M; Wozniak J; Kowatch R; Wagner K; Findling R; Lin D; Robertson-Plouch C; Xu W; Dittmann RW; Biederman J Am J Psychiatry; 2007 Oct; 164(10):1547-56. PubMed ID: 17898346 [TBL] [Abstract][Full Text] [Related]
4. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327 [TBL] [Abstract][Full Text] [Related]
5. A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder. Detke HC; DelBello MP; Landry J; Hoffmann VP; Heinloth A; Dittmann RW J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):922-934. PubMed ID: 27676420 [TBL] [Abstract][Full Text] [Related]
6. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969 [TBL] [Abstract][Full Text] [Related]
7. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514 [TBL] [Abstract][Full Text] [Related]
8. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982 [TBL] [Abstract][Full Text] [Related]
9. The antidepressant effects of risperidone and olanzapine in bipolar disorder. McIntyre RS; Mancini DA; Srinivasan J; McCann S; Konarski JZ; Kennedy SH Can J Clin Pharmacol; 2004; 11(2):e218-26. PubMed ID: 15520475 [TBL] [Abstract][Full Text] [Related]
10. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567 [TBL] [Abstract][Full Text] [Related]
11. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Citrome L; Holt RI; Walker DJ; Hoffmann VP Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734 [TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811 [TBL] [Abstract][Full Text] [Related]
13. Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Mostafavi SA; Solhi M; Mohammadi MR; Akhondzadeh S J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):440-444. PubMed ID: 28339282 [TBL] [Abstract][Full Text] [Related]
14. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. Tohen M; Vieta E; Goodwin GM; Sun B; Amsterdam JD; Banov M; Shekhar A; Aaronson ST; Bardenstein L; Grecu-Gabos I; Tochilov V; Prelipceanu D; Oliff HS; Kryzhanovskaya L; Bowden C J Clin Psychiatry; 2008 Nov; 69(11):1776-89. PubMed ID: 19014751 [TBL] [Abstract][Full Text] [Related]
15. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. Andersen SW; Clemow DB; Corya SA J Clin Psychiatry; 2005 Nov; 66(11):1468-76. PubMed ID: 16420086 [TBL] [Abstract][Full Text] [Related]
16. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842 [TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Tohen M; Calabrese JR; Sachs GS; Banov MD; Detke HC; Risser R; Baker RW; Chou JC; Bowden CL Am J Psychiatry; 2006 Feb; 163(2):247-56. PubMed ID: 16449478 [TBL] [Abstract][Full Text] [Related]
18. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384 [TBL] [Abstract][Full Text] [Related]
19. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. Wozniak J; Mick E; Waxmonsky J; Kotarski M; Hantsoo L; Biederman J J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):539-45. PubMed ID: 19877978 [TBL] [Abstract][Full Text] [Related]
20. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]